By Karlee Weinmann ( August 7, 2013, 4:30 PM EDT) -- Biotech giant Amgen Inc. is closing in on a much-anticipated $9.5 billion buyout of cancer treatment provider Onyx Pharmaceuticals Inc. and could announce finalized terms within the next week, according to a Wednesday report from Reuters. The dealmaking scene has buzzed with speculation over whether — and when — the two could hammer out a sale agreement, sure to be one of the largest the drugmaking sector has seen this year. Onyx spurned a separate bid from Amgen in late June, but has suggested it would go for a bid around $130 per share, the price Amgen is willing to pay....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.